Clarified strategies in terms of scope and prioritisation between studies
Shortened timelines for selecting higher value drug candidates
Lower risk in early development programs and optimisation of R&D costs
Higher project team autonomy in regulatory preclinical and clinical development
Enhanced chances for a much higher project valorisation
Years of experience
Clients
Studied molecules
Latest news
![2024 AFSSI Connexions](https://drugabilis.com/wp-content/uploads/2024/07/drugabilis-2024_bis.png)
2024 AFSSI Connexions
Back to the images of the 2024 AFSSI Connexions in Montpellier (2nd and 3rd of July)... Like last...
more news>
useful ressources
job offers/application
contact us